^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Provecta (rose bengal sodium)

    i
    Other names: PV-10
    Associations

    News

    Trials
    Company:
    Provectus
    Drug class:
    Autophagy inhibitor, WNK1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    PV-10 triggers immunogenic cell death in head and neck squamous cell carcinoma via endoplasmic reticulum stress and apoptosis. (PubMed, Mol Cancer Ther)
    Our data suggests that one of the possible mechanisms by which PV-10 triggers ICD is by inducing endoplasmic reticulum stress, autophagy, and apoptosis. Our findings contribute to further understanding of the underlying mechanisms of PV-10 induced cytotoxicity and to develop future clinical trials in locally recurrent HNSCC.
    Journal
    |
    RAS (Rat Sarcoma Virus) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    Provecta (rose bengal sodium)
    almost2years
    PV-10-MM-1201: PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Provectus Biopharmaceuticals, Inc.
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    Keytruda (pembrolizumab) • Provecta (rose bengal sodium)
    2years
    PV-10-MM-1201: PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Provectus Biopharmaceuticals, Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | N=192 --> 50
    Enrollment closed • Phase classification • Enrollment change • Combination therapy • Checkpoint inhibition • Metastases
    |
    Keytruda (pembrolizumab) • Provecta (rose bengal sodium)
    almost3years
    PV-10-NET-01: A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Provectus Biopharmaceuticals, Inc. | Trial completion date: May 2021 --> Sep 2023
    Trial completion date • Metastases
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR Expression
    |
    Provecta (rose bengal sodium)
    almost4years
    PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=20, Terminated, Provectus Biopharmaceuticals, Inc. | N=32 --> 20
    Enrollment change • Oncolytic virus
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600 • BRAF wild-type
    |
    temozolomide • dacarbazine • Imlygic (talimogene laherparepvec) • Provecta (rose bengal sodium)
    over5years
    [VIRTUAL] A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Initial results in patients refractory to checkpoint blockade (ESMO 2020)
    Methods PV-10-MM-1201 (NCT02557321) is a phase 1b/2 study of IL PV-10 in combination with systemic anti-PD-1 (pembrolizumab, “pembro”) for patients (pts) with advanced cutaneous melanoma; pts must have at least 1 injectable lesion and be candidates for pembro...Funding: Provectus Biopharmaceuticals, Inc. Clinical trial identification: NCT02557321.
    Clinical • P1 data • Checkpoint inhibition
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HMGB1 (High Mobility Group Box 1)
    |
    Keytruda (pembrolizumab) • Provecta (rose bengal sodium)